The DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.
Adjuvant Paclitaxel Plus Carboplatin Compared With Observation in Stage IB Non–Small-Cell Lung Cancer: CALGB 9633 With the Cancer and Leukemia Group B, Radiation Therapy Oncology Group, and North Central Cancer Treatment Group Study Groups
Open accessAbstract
Purpose: Adjuvant chemotherapy for resected non–small-cell lung cancer (NSCLC) is now accepted on the basis of several randomized clinical trials (RCTs) that demonstrated improved survival. Although there is strong evidence that adjuvant chemotherapy is effective in stages II and IIIA NSCLC, its utility in stage IB disease is unclear. This report provides a mature analysis of Cancer and Leukemia Group B (CALGB) 9633, the only RCT designed specifically for stage IB NSCLC. Patients and Methods: Within 4 to 8 weeks of resection, patients were randomly assigned to adjuvant chemotherapy or observation. Eligible patients had pathologically confirmed T2N0 NSCLC and had undergone lobectomy or pneumonectomy. Chemotherapy consisted of paclitaxel 200 mg/m 2 intravenously over 3 hours and carboplatin at an area under the curve dose of 6 mg/mL per minute intravenously over 45 to 60 minutes every 3 weeks for four cycles. The primary end point was overall survival. Results: Three hundred-forty-four patients were randomly assigned. Median follow-up was 74 months. Groups were well-balanced with regard to demographics, histology, and extent of surgery. Grades 3 to 4 neutropenia were the predominant toxicity; there were no treatment-related deaths. Survival was not significantly different (hazard ratio [HR], 0.83; CI, 0.64 to 1.08; P = .12). However, exploratory analysis demonstrated a significant survival difference in favor of adjuvant chemotherapy for patients who had tumors ≥ 4 cm in diameter (HR, 0.69; CI, 0.48 to 0.99; P = .043). Conclusion: Because a significant survival advantage was not observed across the entire cohort, adjuvant chemotherapy should not be considered standard care in stage IB NSCLC. Given the magnitude of observed survival differences, CALGB 9633 was underpowered to detect small but clinically meaningful improvements. A statistically significant survival advantage for patients who had tumors ≥ 4 cm supports consideration of adjuvant paclitaxel/carboplatin for stage IB patients who have large tumors.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Comparison of Four Chemotherapy Regimens for Advanced Non–Small-Cell Lung Cancer
Schiller, J. H., Harrington, D., Belani, C. P., Langer, C., Sandler, A., Krook, J., Zhu, J., & Johnson, D. H. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa011954 · Cited by 4,955
Revisions in the International System for Staging Lung Cancer
Mountain, C. F. (1997) · Chest · doi:10.1378/chest.111.6.1710 · Cited by 4,565
Brocken, P., van der Heijden, H. F. M., Dekhuijzen, P. N. R., Peters-Bax, L., & de Geus-Oei, L.-F. (2014) · Respiration · doi:10.1159/000347096 · Cited by 4,002
COMPARISON OF FOUR CHEMOTHERAPY REGIMENS FOR ADVANCED NON-SMALL-CELL LUNG CANCER
Chiller, J. O. H. S., Arrington, D. A. H., Elani, C. H. P. B., Anger, C., Andler, A. L. S., Rook, J. A. K., Hu, J., & Ohnson, D. A. H. J. (2002) · Cited by 3,730
Goldstraw, P., Crowley, J., Chansky, K., Giroux, D. J., Groome, P. A., Rami-Porta, R., Postmus, P. E., Rusch, V., & Sobin, L. (2007) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e31812f3c1a · Cited by 3,655
A Multiple Testing Procedure for Clinical Trials
O'Brien, P. C., & Fleming, T. R. (1979) · Biometrics · doi:10.2307/2530245 · Cited by 3,311
(2004) · New England Journal of Medicine · doi:10.1056/nejmoa031644 · Cited by 2,335
Discrete sequential boundaries for clinical trials
GORDON LAN, K. K., & DEMETS, D. L. (1983) · Biometrika · doi:10.1093/biomet/70.3.659 · Cited by 2,310
Vinorelbine plus Cisplatin vs. Observation in Resected Non–Small-Cell Lung Cancer
Winton, T., Livingston, R., Johnson, D., Rigas, J., Johnston, M., Butts, C., Cormier, Y., Goss, G., Inculet, R., Vallieres, E., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa043623 · Cited by 1,810
Postmus, P. E., Brambilla, E., Chansky, K., Crowley, J., Goldstraw, P., Patz, E. F., & Yokomise, H. (2007) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e31811f4703 · Cited by 1,594
Douillard, J.-Y., Rosell, R., De Lena, M., Carpagnano, F., Ramlau, R., Gonzáles-Larriba, J. L., Grodzki, T., Pereira, J. R., Le Groumellec, A., Lorusso, V., et al. (2006) · The Lancet Oncology · doi:10.1016/s1470-2045(06)70804-x · Cited by 1,573
Kelly, K., Crowley, J., Bunn, P. A., Presant, C. A., Grevstad, P. K., Moinpour, C. M., Ramsey, S. D., Wozniak, A. J., Weiss, G. R., Moore, D. F., et al. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.13.3210 · Cited by 1,123
Scagliotti, G. V., De Marinis, F., Rinaldi, M., Crinò, L., Gridelli, C., Ricci, S., Matano, E., Boni, C., Marangolo, M., Failla, G., et al. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.02.068 · Cited by 889
A Randomized Trial of Adjuvant Chemotherapy with Uracil–Tegafur for Adenocarcinoma of the Lung
Kato, H., Ichinose, Y., Ohta, M., Hata, E., Tsubota, N., Tada, H., Watanabe, Y., Wada, H., Tsuboi, M., Hamajima, N., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa032792 · Cited by 818
Rami-Porta, R., Ball, D., Crowley, J., Giroux, D. J., Jett, J., Travis, W. D., Tsuboi, M., Vallières, E., & Goldstraw, P. (2007) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e31807a2f81 · Cited by 637
Ardizzoni, A., Boni, L., Tiseo, M., Fossella, F. V., Schiller, J. H., Paesmans, M., Radosavljevic, D., Paccagnella, A., Zatloukal, P., Mazzanti, P., et al. (2007) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djk196 · Cited by 612
Lilenbaum, R. C., Herndon, J. E., List, M. A., Desch, C., Watson, D. M., Miller, A. A., Graziano, S. L., Perry, M. C., Saville, W., Chahinian, P., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.07.172 · Cited by 444
Self-citationStrauss, G. M., Herndon, J. E., Maddaus, M. A., Johnstone, D. W., Johnson, E. A., Watson, D. M., Sugarbaker, D. J., Schilsky, R. L., & Green, M. R. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.22.14_suppl.7019 · Cited by 380
Self-citationHotta, K., Matsuo, K., Ueoka, H., Kiura, K., Tabata, M., & Tanimoto, M. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.02.109 · Cited by 364
Pisters, K. M. W., Evans, W. K., Azzoli, C. G., Kris, M. G., Smith, C. A., Desch, C. E., Somerfield, M. R., Brouwers, M. C., Darling, G., Ellis, P. M., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.14.1226 · Cited by 363
Langer, C. J., Leighton, J. C., Comis, R. L., O'Dwyer, P. J., McAleer, C. A., Bonjo, C. A., Engstrom, P. F., Litwin, S., & Ozols, R. F. (1995) · Journal of Clinical Oncology · doi:10.1200/jco.1995.13.8.1860 · Cited by 295
Pampallona, S., & Tsiatis, A. A. (1994) · Journal of Statistical Planning and Inference · doi:10.1016/0378-3758(94)90187-2 · Cited by 219
Strauss, G. M., Herndon, J. E., Maddaus, M. A., Johnstone, D. W., Johnson, E. A., Watson, D. M., Sugarbaker, D. J., Schilsky, R. A., Vokes, E. E., & Green, M. R. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2006.24.18_suppl.7007 · Cited by 178
Self-citationPignon, J., Tribodet, H., Scagliotti, G. V., Douillard, J., Shepherd, F. A., Stephens, R. J., & Chevalier, T. L. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2006.24.18_suppl.7008 · Cited by 157
Moinpour, C. M., Wu, J., Donaldson, G. W., Liepa, A. M., Melemed, A. S., O’Shaughnessy, J., Rappold, E., & Albain, K. S. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.22.14_suppl.621 · Cited by 51
Dunant, A., Pignon, J., & Thierry Le Chevalier on behalf of the International Adjuvant Lung Cancer Trial Collaborative Group (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-9006 · Cited by 45
Adjuvant chemotherapy in stage IB nonsmall cell lung cancer
Wauters, I., & Vansteenkiste, J. (2009) · Breathe · doi:10.1183/18106838.0504.361 · Cited by 11
Management of early-stage lung cancer: past, present, and future adjuvant trials.
Strauss, G. M. (2006) · PubMed · Cited by 8
Self-citationAdjuvant Therapy for Early Lung Cancer: Reflections and Perspectives
Pignon, J., & Massard, C. (2006) · Cited by 5
Cited by
Postmus, P. E., Kerr, K. M., Oudkerk, M., Senan, S., Waller, D. A., Vansteenkiste, J., Escriu, C., & Peters, S. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx222 · Cited by 2,302
Treatment of Stage I and II Non-small Cell Lung Cancer
Howington, J. A., Blum, M. G., Chang, A. C., Balekian, A. A., & Murthy, S. C. (2013) · Chest · doi:10.1378/chest.12-2359 · Cited by 1,440
_, _. (2008) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2008.0021 · Cited by 735
Management of non-small-cell lung cancer: recent developments
Reck, M., Heigener, D. F., Mok, T., Soria, J.-C., & Rabe, K. F. (2013) · The Lancet · doi:10.1016/s0140-6736(13)61502-0 · Cited by 714
Non‐small cell lung cancer in China
Chen, P., Liu, Y., Wen, Y., & Zhou, C. (2022) · Cancer Communications · doi:10.1002/cac2.12359 · Cited by 656
Metadata
- Authors
- Strauss, G. M., Herndon, J. E., Maddaus, M. A., Johnstone, D. W., Johnson, E. A., Harpole, D. H., Gillenwater, H. H., Watson, D. M., Sugarbaker, D. J., Schilsky, R. L., Vokes, E. E., & Green, M. R.
- Venue
- Journal of Clinical Oncology
- Published
- 2008-11-01
- Volume
- 26
- Issue
- 31
- Pages
- 5043-5051
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2114855342
- Cited by
- 974
- References
- 29
- FWCI
- 49.81
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.